ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Exploratory investigation of OCTA-VISTA for longitudinal monitoring of neovascular age-related macular degeneration treatment.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study investigated the feasibility of a quantitative blood flow measurement program combining optical coherence tomography angiography (OCTA) and variable interscan time analysis (VISTA) in neovascular age-related macular degeneration (nAMD) treatment.
methodsA prototype OCT device with a unique scan pattern acquired OCTA-VISTA images from 11 eyes of 10 patients with treatment-naïve nAMD and macular neovascularization (MNV) at three time points: pretreatment, immediately posttreatment, and 1 month later. MNV regions were segmented from the outer retinal slab. Blood flow parameters, which were surrogate markers of velocity, and neovascular vessel area (NVA) were evaluated. Characteristic changes were analyzed in the MNV vessels, which were classified by diameter as follows: capillaries (≤ 20 μm), medium vessels (20–40 μm), and large vessels (≥ 40 μm).
resultsQuantitative analysis was feasible in five eyes from five patients. In eyes with marked NVA reduction, flow parameters decreased from baseline to 1 month by 37.9% in capillaries, 39.7% in medium vessels, and 48.3% in large vessels. In partial responders with limited NVA changes, the corresponding reductions were 29.6%, 23.5%, and 14.2%, respectively. Scatter plot analyses demonstrated that changes in NVA and flow parameters generally occurred in parallel.
conclusionsOCTA-VISTA enabled quantitative tracking of flow parameters by vessel diameter before and after MNV treatment in some patients. This methodology may benefit treatment efficacy monitoring and evaluating disease progression in nAMD.
Indexed as
Identifiers
41518383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.